Imavita is proud to announce the recent recruitment of Maud Chusseau and Julia Rochotte.
Maud Chusseau, MSc, Research Scientist, Maud is graduated from University of Lyon, France (Master Pharmacology / Animal experimentation 2007). Maud has several industry experiences (SeleXel, Endotis Pharma, Galapagos, Servier). Maud works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation and has experience in qPCR, animals surgery and small animal imaging.
Julia Rochotte, PhD, Immunologist, Project Leader, Julia is a young PhD graduated on 2014. She has spent 7 years at the laboratory of the Center of Oncology Research of Toulouse (Centre de Recherche en Cancérologie de Toulouse (CRCT) U1037 INSERM / UPS / CNRS) with an important background in immunology and immuno-oncology.
This 3-year project will focus on the fields of oncology, cardiovascular and neurology, for which 4 work teams have been created:
Synthesis, purification and structural analysis of radiolabelling precursors with Fluor 18 and development of various syntheses of radio-fluorinated molecules,
Production of radiolabelled molecules for injection in pre-clinical models,
Development and implementation of animal pathological models, PET/CT imaging and quantitative analysis of imaging data for therapeutic targeting validation,
Production in pharmaceutical quality and use of radiolabelled products in clinical trials
IMAVITA will actively participate in this project by providing technical and scientific expertise and relevant preclinical models of cancer, atherosclerosis and Alzheimer’s disease.
This project will allow IMAVITA to develop new animal models, access custom and innovative radio tagging skills, explore existing preclinical models in PET/CT imaging and develop new translational services in preclinical and clinical imaging.
Ce projet de 3 ans sera axé dans les domaines de l’oncologie, cardio-vasculaire et neurologie et pour lesquels 4 équipes de travail ont été créées :
1/ Synthèse, purification et analyse structurale de précurseurs de radio-marquage avec le Fluor 18 et mise au point des diverses synthèses de molécules radio-fluorées,
2/ Production des molécules radio-marquées pour injection dans des modèles pré-cliniques,
3/ Développement et mise en place des modèles animaux pathologiques, imagerie PET/CT et analyse quantitative des données d’imagerie pour validation du ciblage thérapeutique,
4/ Production en qualité pharmaceutique et utilisation des productions de produits radio-marqués dans le cadre d’essais cliniques
La société IMAVITA participera activement à ce projet par la mise à disposition de compétences techniques et scientifiques et la fourniture de modèles précliniques pertinents de cancer, d’athérosclérose et de maladie d’Alzheimer.
Ce projet permettra à IMAVITA le développement de nouveaux modèles animaux, l’accès à des compétences de radio-marquage à façon et innovants, l’exploration en imagerie PET/CT de modèles précliniques existants et de nouveaux services translationnels en imagerie préclinique et clinique.
This imaging technique is available for in vivo (isofluran anesthesia) and/or ex vivo imaging and permits to accelerate evaluation of efficacy of compounds during course of projects or on sample collection.
Image example (atopic dermatitis model / ear):
Imavita developed a quantification algorithm to permit measurement of epidermis thickness immediatley after image capture. Correlation and validation of this imaging biomarker was fully performed in comparison to histology.
Imavita is proud to announce the acquisition of new Optical Coherence Tomography apparatus.
Since september 2017, Imavita is working on this innovative imaging system (OQ Labscope / Lumedica) which will permit to generate non-invasive, surface tissue quantitative data for pre-clinical models in place at Imavita in Applications of interest, principally in the area of dermatology.
The benefits of this in vivo imaging modality are:
Easily and efficiently obtain calibrated quantitative data in preclinical models
Deepen understanding of disease mechanisms, disease progression and therapeutic responses
Manage costs and capture time course data by avoiding sacrifice of animal models
For more informations, do not hesitate to contact us.
Imavita is proud to announce the recent recruitment of Elisabeth Bonnard and Jeanne Chapel.
Dr Elisabeth Bonnard, Neuropharmacologist, PhD, Project Leader, was graduated on 2004 at the l’Institut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse. She has 10 years of experience as head of pharmacology at PharmaLeads, Paris, France. She brings experience in preclinical development, in vivo models in neurology. Elisabeth will help in the implementation of new preclinical models in the areas of neurology and dermatology.
Jeanne Chapel, MSc, Research Scientist, is graduated from University of Paul Sabatier, Toulouse, France (Master Bioingéniérie 2015). Jeanne will work in the in vitro lab and will help in applications of in vivo models for drug efficacy evaluation.
Imavita is proud to announce the acquisition of new Fluorescence Molecular Tomography imaging apparatus for the evaluation of its models.
Since october 2016, a Fluorescence Tomography system was acquired (FMT2500, Perkin Elmer). The FMT2500 fluorescence tomography imaging system provides the greatest utility of the FMT Systems with the ability to quantitate up to 2 fluorophores simultaneously. It comes with 2 excitation laser channels (680 & 750 nm).
This imaging modality will permit to generate non-invasive, deep tissue quantitative data for pre-clinical models in place at Imavita in Applications of interest.
The benefits of this in vivo imaging modality are:
Easily and efficiently obtain calibrated quantitative data in preclinical models
Measure and monitor multiple biological processes simultaneously
Obtain functional and biological data to improve study designs and enhance decision making
Generate 3D, information-rich results
Complement the molecular functional findings of fluorescence imaging with other anatomical and/or functional modalities like CT, MRI, PET and
SPECT
Deepen understanding of disease mechanisms, disease progression and therapeutic responses
Manage costs and capture time course data by avoiding sacrifice of animal models
For more informations, do not hesitate to contact us.
Imavita has Research Tax Credit agreement / CIR (“Crédit Impôt Recherche“) for years 2016 to 2020 (obtained on April 22th 2016 / download pdf file of Research Tax Credit Accreditation).
This agreement, obtained from the french authorities, permits to the clients working with Imavita to refund R&D spendings to their corporate taxes.
All companies incurring R&D expenses are eligible to receive France’s research tax credit, regardless of their size, business sector and nationality.
The tax credit covers 30% of all R&D expenses and covers all R&D spending: Salaries, social security contributions, amortization and depreciation allowances, operating costs, subcontracting, patents and monitoring.
The scope of SME spending eligible for the research tax credit has been extended as of 2013 to cover innovation expenses arising from designing prototypes, as well as pilot plants for new products. These expenses are now included in the research tax credit base, at a rate of 20%.
For income tax purposes, the definition of a qualified activity for the Research & Experimentation (R&E) Tax Credit or the research and development (R&D) Tax Credit includes not only the development of new products, but also improvements to products, processes, techniques, formulas, patents, and software applications.
